 NEW YORK, Sept. 15, 2021 GLOBE NEWSWIRE -- atai Life Sciences Nasdaq: ATAI atai, a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced it has entered into an amended and restated loan agreement Loan Agreement with strategic partner IntelGenx Technologies Corp. IntelGenx to support IntelGenxs conditionally approved graduation from the TSX Venture Exchange to the Toronto Stock Exchange TSX. Completion of the uplisting and the commencement of trading of IntelGenxs common shares, 8 convertible debentures with a maturity date of June 30, 2022, and share purchase warrants expiring on February 11, 2023 is subject to the satisfaction by IntelGenx of all of the final conditions of listing. 